Abstract:Automating brain tumor segmentation using deep learning methods is an ongoing challenge in medical imaging. Multiple lingering issues exist including domain-shift and applications in low-resource settings which brings a unique set of challenges including scarcity of data. As a step towards solving these specific problems, we propose Convolutional adapter-inspired Parameter-efficient Fine-tuning (PEFT) of MedNeXt architecture. To validate our idea, we show our method performs comparable to full fine-tuning with the added benefit of reduced training compute using BraTS-2021 as pre-training dataset and BraTS-Africa as the fine-tuning dataset. BraTS-Africa consists of a small dataset (60 train / 35 validation) from the Sub-Saharan African population with marked shift in the MRI quality compared to BraTS-2021 (1251 train samples). We first show that models trained on BraTS-2021 dataset do not generalize well to BraTS-Africa as shown by 20% reduction in mean dice on BraTS-Africa validation samples. Then, we show that PEFT can leverage both the BraTS-2021 and BraTS-Africa dataset to obtain mean dice of 0.8 compared to 0.72 when trained only on BraTS-Africa. Finally, We show that PEFT (0.80 mean dice) results in comparable performance to full fine-tuning (0.77 mean dice) which may show PEFT to be better on average but the boxplots show that full finetuning results is much lesser variance in performance. Nevertheless, on disaggregation of the dice metrics, we find that the model has tendency to oversegment as shown by high specificity (0.99) compared to relatively low sensitivity(0.75). The source code is available at https://github.com/CAMERA-MRI/SPARK2024/tree/main/PEFT_MedNeXt
Abstract:A critical challenge for tumour segmentation models is the ability to adapt to diverse clinical settings, particularly when applied to poor-quality neuroimaging data. The uncertainty surrounding this adaptation stems from the lack of representative datasets, leaving top-performing models without exposure to common artifacts found in MRI data throughout Sub-Saharan Africa (SSA). We replicated a framework that secured the 2nd position in the 2022 BraTS competition to investigate the impact of dataset composition on model performance and pursued four distinct approaches through training a model with: 1) BraTS-Africa data only (train_SSA, N=60), 2) BraTS-Adult Glioma data only (train_GLI, N=1251), 3) both datasets together (train_ALL, N=1311), and 4) through further training the train_GLI model with BraTS-Africa data (train_ftSSA). Notably, training on a smaller low-quality dataset alone (train_SSA) yielded subpar results, and training on a larger high-quality dataset alone (train_GLI) struggled to delineate oedematous tissue in the low-quality validation set. The most promising approach (train_ftSSA) involved pre-training a model on high-quality neuroimages and then fine-tuning it on the smaller, low-quality dataset. This approach outperformed the others, ranking second in the MICCAI BraTS Africa global challenge external testing phase. These findings underscore the significance of larger sample sizes and broad exposure to data in improving segmentation performance. Furthermore, we demonstrated that there is potential for improving such models by fine-tuning them with a wider range of data locally.
Abstract:Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality rates across the Global North, while chances of survival among individuals in low- and middle-income countries (LMICs) remain unchanged and are significantly worse in Sub-Saharan Africa (SSA) populations. Long-term survival with glioma is associated with the identification of appropriate pathological features on brain MRI and confirmation by histopathology. Since 2012, the Brain Tumor Segmentation (BraTS) Challenge have evaluated state-of-the-art machine learning methods to detect, characterize, and classify gliomas. However, it is unclear if the state-of-the-art methods can be widely implemented in SSA given the extensive use of lower-quality MRI technology, which produces poor image contrast and resolution and more importantly, the propensity for late presentation of disease at advanced stages as well as the unique characteristics of gliomas in SSA (i.e., suspected higher rates of gliomatosis cerebri). Thus, the BraTS-Africa Challenge provides a unique opportunity to include brain MRI glioma cases from SSA in global efforts through the BraTS Challenge to develop and evaluate computer-aided-diagnostic (CAD) methods for the detection and characterization of glioma in resource-limited settings, where the potential for CAD tools to transform healthcare are more likely.